Gerresheimer reported Q2 recovery: Gerresheimer stock gains 1.66 percent

Published on 10/26/2026 at 09:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 adjusted EBITDA hit EUR 102.00 million, up EUR 35.00 million. Gerresheimer stock costs EUR 31.86 on October 26, 2026, 1.66 percent above Xetra.

Operational rebound and scheduled reports

Preliminary second-quarter revenue reached EUR 578 million on September 30, 2026.
Adjusted EBITDA rose from EUR 67 million to EUR 102 million in the second quarter.
Gerresheimer stock trades at EUR 31.86 at 9:38 a.m. CET at Lang & Schwarz on October 26, 2026, 1.66 percent above the Xetra close of October 23, 2026.
The final first-half report is scheduled for the end of November 2026.

Pop-Art-Comic eines Laborwissenschaftlers mit Glasampulle im Labor — Gerresheimer AG, ISIN DE000A0LD6E6, wird hier als farbenfrohe Pop-Art-Comicszene eines Pharmalaborwissenschaftlers künstlerisch dargestellt, Illustration mit AI erstellt.

Gerresheimer stock (ISIN DE000A0LD6E6) was trading at EUR 31.86 at Lang & Schwarz on October 26, 2026, at 9:38 a.m. CET, up 1.66 percent versus the Xetra close of October 23, 2026 at EUR 31.34. The move follows a preliminary second-quarter recovery that lifted adjusted EBITDA by EUR 35 million from the first quarter, as Gerresheimer reported on September 30, 2026.

Q2 recovery is uneven

Revenue reached EUR 578 million in the second quarter of 2026, up from EUR 523 million in the first quarter. Adjusted EBITDA rose from EUR 67 million to EUR 102 million, a 52.24 percent quarter-over-quarter increase, while the adjusted EBITDA margin reached 17.6 percent.

The rebound did not erase the prior-year comparison. First-half revenue was EUR 1.10 billion, down from EUR 1.14 billion in the first half of 2025, while adjusted EBITDA fell to EUR 168 million from EUR 224 million. MarketScreener reported that stronger demand for drug delivery devices helped, while injection vials remained weak.

What does recovery mean for margins?

Containment and Delivery Systems provided the clearest support. Its first-half adjusted EBITDA reached EUR 135 million, including EUR 74 million in the second quarter, and its quarterly margin improved to 23.9 percent. Primary Injectable Solutions generated EUR 212 million of first-half revenue and EUR 16 million of adjusted EBITDA, showing where utilization pressure remains concentrated.

Three milestones shape the stock

On August 27, 2026, the first-quarter statement showed revenue of EUR 474.90 million and adjusted EBITDA of EUR 49.50 million, according to FinancialFilings. On September 30, 2026, the second-quarter release reported EUR 578 million of revenue and EUR 102 million of adjusted EBITDA. On October 26, 2026, the Lang & Schwarz quote stood at EUR 31.86.

Reports due in November and December

Gerresheimer plans to publish the final first-half report at the end of November 2026, followed by its third-quarter statement in December 2026, according to the company's investor-relations calendar.

Stock remains below its yearly high

The current euro quote is EUR 1.1 billion in market capitalization, while the 52-week range is EUR 14.83 to EUR 33.28. The recovery case therefore depends on stronger second-half earnings and progress on the company's restructuring and portfolio measures.

Gerresheimer was trading at EUR 31.86 at Lang & Schwarz on October 26, 2026, at 9:38 a.m. CET, 1.66 percent above the Xetra close of October 23, 2026 at EUR 31.34. The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.